These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 37270920)

  • 1. Cost-Effectiveness of All-Oral Regimens for the Treatment of Multidrug-Resistant Tuberculosis in Korea: Comparison With Conventional Injectable-Containing Regimens.
    Park HY; Kwon JW; Kim HL; Kwon SH; Nam JH; Min S; Oh IS; Bea S; Choi SH
    J Korean Med Sci; 2023 May; 38(21):e167. PubMed ID: 37270920
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany.
    Wirth D; Dass R; Hettle R
    BMC Health Serv Res; 2017 Mar; 17(1):182. PubMed ID: 28270207
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The cost-effectiveness of a bedaquiline-containing short-course regimen for the treatment of multidrug-resistant tuberculosis in South Africa.
    Mpobela Agnarson A; Williams A; Kambili C; Mattson G; Metz L
    Expert Rev Anti Infect Ther; 2020 May; 18(5):475-483. PubMed ID: 32186925
    [No Abstract]   [Full Text] [Related]  

  • 4. Cost-effectiveness of bedaquiline or delamanid plus background regimen for multidrug-resistant tuberculosis in a high-income intermediate burden city of China.
    Fan Q; Ming WK; Yip WY; You JHS
    Int J Infect Dis; 2019 Jan; 78():44-49. PubMed ID: 30342251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of Bedaquiline for the Treatment of Multidrug-resistant Tuberculosis in the Republic of Korea.
    Park HY; Ku HM; Sohn HS; Seo HS; Yung Lee H; Hwa Lim K; Kwon JW
    Clin Ther; 2016 Mar; 38(3):655-67.e1-2. PubMed ID: 26907504
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost comparison of nine-month treatment regimens with 20-month standardized care for the treatment of rifampicin-resistant/multi-drug resistant tuberculosis in Nigeria.
    Bada FO; Blok N; Okpokoro E; Dutt S; Akolo C; Dakum P; Abimiku A
    PLoS One; 2020; 15(12):e0241065. PubMed ID: 33259492
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of treating multidrug-resistant tuberculosis.
    Resch SC; Salomon JA; Murray M; Weinstein MC
    PLoS Med; 2006 Jul; 3(7):e241. PubMed ID: 16796403
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economic evaluation protocol of a short, all-oral bedaquiline-containing regimen for the treatment of rifampicin-resistant tuberculosis from the STREAM trial.
    Rosu L; Madan J; Worrall E; Tomeny E; Squire B;
    BMJ Open; 2020 Dec; 10(12):e042390. PubMed ID: 33371043
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic evaluation of shortened, bedaquiline-containing treatment regimens for rifampicin-resistant tuberculosis (STREAM stage 2): a within-trial analysis of a randomised controlled trial.
    Rosu L; Madan JJ; Tomeny EM; Muniyandi M; Nidoi J; Girma M; Vilc V; Bindroo P; Dhandhukiya R; Bayissa AK; Meressa D; Narendran G; Solanki R; Bhatnagar AK; Tudor E; Kirenga B; Meredith SK; Nunn AJ; Bronson G; Rusen ID; Squire SB; Worrall E;
    Lancet Glob Health; 2023 Feb; 11(2):e265-e277. PubMed ID: 36565704
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bedaquiline-based treatment for extensively drug-resistant tuberculosis in South Africa: A cost-effectiveness analysis.
    Fekadu G; Yao J; You JHS
    PLoS One; 2022; 17(8):e0272770. PubMed ID: 35930574
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incremental Cost Effectiveness of Bedaquiline for the Treatment of Rifampicin-Resistant Tuberculosis in South Africa: Model-Based Analysis.
    Schnippel K; Firnhaber C; Conradie F; Ndjeka N; Sinanovic E
    Appl Health Econ Health Policy; 2018 Feb; 16(1):43-54. PubMed ID: 28980217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost effectiveness of treating multi-drug resistant tuberculosis by adding Deltyba™ to background regimens in Germany.
    Diel R; Hittel N; Schaberg T
    Respir Med; 2015 May; 109(5):632-41. PubMed ID: 25862597
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bedaquiline- versus injectable-containing drug-resistant tuberculosis regimens: a cost-effectiveness analysis.
    Ionescu AM; Mpobela Agnarson A; Kambili C; Metz L; Kfoury J; Wang S; Williams A; Singh V; Thomas A
    Expert Rev Pharmacoecon Outcomes Res; 2018 Dec; 18(6):677-689. PubMed ID: 30073886
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of improving patients' adherence to tuberculosis treatment in South Korea using discrete event simulation.
    Min S; Kwon SH; Lee EK; Nam JH
    J Infect Public Health; 2024 Mar; 17(3):478-485. PubMed ID: 38271751
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of adverse drug reactions on the incremental cost-effectiveness of bedaquiline for drug-resistant tuberculosis.
    Schnippel K; Firnhaber C; Page-Shipp L; Sinanovic E
    Int J Tuberc Lung Dis; 2018 Aug; 22(8):918-925. PubMed ID: 29991402
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.
    Main C; Bojke L; Griffin S; Norman G; Barbieri M; Mather L; Stark D; Palmer S; Riemsma R
    Health Technol Assess; 2006 Mar; 10(9):1-132. iii-iv. PubMed ID: 16545208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Programme costs of longer and shorter tuberculosis drug regimens and drug import: a modelling study for Karakalpakstan, Uzbekistan.
    Kohler S; Sitali N; Achar J; Paul N
    ERJ Open Res; 2022 Jan; 8(1):. PubMed ID: 35350276
    [TBL] [Abstract][Full Text] [Related]  

  • 18. All-oral longer regimens are effective for the management of multidrug-resistant tuberculosis in high-burden settings.
    Khan PY; Franke MF; Hewison C; Seung KJ; Huerga H; Atwood S; Ahmed S; Khan M; Sultana T; Manzur-Ul-Alam M; Vo LNQ; Lecca L; Yae K; Kozhabekov S; Tamirat M; Gelin A; Vilbrun SC; Kikvidze M; Faqirzai J; Kadyrov A; Skrahina A; Mesic A; Avagyan N; Bastard M; Rich ML; Khan U; Mitnick CD
    Eur Respir J; 2022 Jan; 59(1):. PubMed ID: 34140298
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-Effectiveness Analysis of Combined Chemotherapy Regimen Containing Bedaquiline in the Treatment of Multidrug-Resistant Tuberculosis in China.
    Xu CH; Qiu YP; He ZL; Hu DM; Yue X; Chen ZD; Xu YY; Zhao YL
    Biomed Environ Sci; 2023 Jun; 36(6):501-509. PubMed ID: 37424243
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mycobactericidal Effects of Different Regimens Measured by Molecular Bacterial Load Assay among People Treated for Multidrug-Resistant Tuberculosis in Tanzania.
    Mbelele PM; Mpolya EA; Sauli E; Mtafya B; Ntinginya NE; Addo KK; Kreppel K; Mfinanga S; Phillips PPJ; Gillespie SH; Heysell SK; Sabiiti W; Mpagama SG
    J Clin Microbiol; 2021 Mar; 59(4):. PubMed ID: 33536294
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.